Infliximab biosimilar safe, effective for Crohn’s disease

The biosimilar of infliximab, CT-P13, demonstrated equivalency in safety and efficacy for the treatment of Crohn’s disease, according to data published in Annals of Internal Medicine.
“CT-P13 is a biosimilar of the reference product infliximab, with demonstrated efficacy and safety for some inflammatory arthritides,” Antoine Meyer, MD, from Hôpital Bicêtre, Le Kremlin-Bicêtre, France, and colleagues wrote. “It was approved for the treatment of Crohn’s disease on that basis, without specific studies examining its effects in Crohn’s disease.”

Source link

Related posts

Elsewhere in The AGA Journals


CME Exam 3: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis


Cold Snare Resection for Polyps ≥10 mm


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy